Table 1 Distribution and characteristics of intermediate-risk AML patients transplanted in CR1 MRD negative.

From: Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT

  

AUTO group

HAPLO group

p-value

Number of patients

 

547

575

 

Year of transplant

Median (min-max)

2016 (2010–2021)

2018 (2010–2021)

<0.0001

Follow-up (months)

Median [IQR]

range

45 [41–49] 1–144

34 [30–36] 1–128

<0.0001

Country

China

63 (11.5%)

164 (28.5)

<0.0001

Other

484 (88.5%)

411 (71.5)

 

Patient age at HSCT (years)

Median [IQR]

54 [43–62]

49 [37–60]

<0.0001

Patient sex

Male

278 (50.8%)

328 (57%)

0.72

Female

269 (49.2%)

247 (43%)

 

Year of HSCT

Median [range]

2016 [2010–2021]

2018 [2010–2021]

<0.0001

FLT3 mutation status

FLT3-wt

418 (76.4%)

325 (56.5%)

<0.0001

FLT3-ITD

129 (23.6%)

250 (43.5%)

 

NPM1 mutation status

NPM1wt

210 (38.4%)

327 (56.9%)

<0.0001

NPM1 mutated

324 (59.2%)

188 (32.7%)

 

Missing

13 (2.4%)

60 (10.4%)

 

Karnofsky score at transplant

<90

82 (15%)

188 (32.7%)

<0.0001

≥90

433 (79.2%)

335 (58.3%)

 

Missing

32 (5.8%)

52 (9%)

 

Patient CMV status

Positive

110 (20.1%)

343 (59.7%)

0.8

Negative

64 (11.7%)

209 (36.3%)

 

Missing

373 (68.2%)

23 (4%)

 

Stem cell source

BM

12 (2.2%)

118 (20.5%)

 

PB

530 (96.9%)

314 (54.6%)

 

BM + PB

5 (0.9%)

45 (7.8%)

 

CB with BM/PB

0

98 (17.1%)

 

Conditioning regimen

BU/CY-based

294 (53.8%)

143 (24.9%)

 

BU/MEL-based

61 (11.2%)

0

 

BU/FLU-based

30 (5.5%)

98 (17.1%)

 

FLU/TBI-based

0

55 (9.6%)

 

BUVP16:

45 (8.2%)

0

 

TBF-based

0

203 (35.4%)

 

GVHD prevention

Associated IS

PTCY

-

292 (51.5%)

 

In vivo TCD

-

 184 (32.5%)

 

Both

 

52 (9.2%)

 

Other

 

39 (6.8%)

 

CSA + MMF

-

213 (37.6%)

 

CSA + MTX + MMF

-

132 (23.3%)

 

MMF + TACRO

-

115 (20.3%)

 

OTHER

-

107 (18.8%)

 

Interval Diag-HSCT (months)

Median [range]

4.7 [1–53]

5.2 [1–61]

0.0003

  1. IQR interquartile range, HSCT hematopoieticstem cell transplantation, wt wild-type, GVHD graft-versus-hostdisease, CMV cytomegalovirus, BM bonemarrow, PB peripheralblood, CB cordblood, BU busulfan, CY cyclophosphamide, MEL melphalan, FLU fludarabine, TBI totalbody irradiation, TBF thiotepa-busulfan-fludarabine, PTCy post-transplantcyclophosphamide, ATG anti-thymocyteglobulin, CSA cyclosporinA, MMF mycophenolatemofetil, MTX methotrexate.
Back to article page